MolPharm xPharm- The Comprehensive Pharmacology Reference

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by HAKALA, M. T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by HAKALA, M. T.

Molecular Pharmacology, Vol 4, 162-167, Copyright © 1968 by the American Society for Pharmacology and Experimental Therapeutics

The Essential SH-Groups in Folate Reductase

MAIRE T. HAKALA 1

1 Department of Experimental Therapeutics, Roswell Park Memorial Institute, Buffalo, New York 14203

The number of essential SH-groups per amethopterin binding site has been determined in several preparations of folate reductase derived from a subline of S-180 cells grown in vitro. The content of folate reductase in terms of amethopterin binding sites varied in the different preparations between 15 and 20 mµmoles per milligram of protein and was based on titrations with amethopterin. In every preparation two SH-groups per binding site were essential for enzymatic activity and amethopterin binding. These two were protected against 5,5'-dithiobis-(2-nitrobenzoic acid) by TPNH, folate, and amethopterin and by low temperatures. The remainder of the SH-groups, which varied in different preparations, could not be protected and reacted with SH-reagent without interfering with the enymatic activity or amethopterin binding capacity. Folate reductase was found to be sensitive to inactivation by urea, which also accelerated the reaction with the SH-reagent.

Note:
ACKNOWLEDGMENTS The author wishes to express her appreciation to Mrs. L. Kenny and Miss E.-M. Suolinna for assistance in this study. This investigation was supported in part by research grant CA-04175 from the National Cancer Institute of the U.S. Public Health Service.

Submitted on October 13, 1967







Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 1968 by the American Society for Pharmacology and Experimental Therapeutics